Welch Group LLC Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV)
Welch Group LLC Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV)
Welch Group LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 2.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 370,861 shares of the company's stock after selling 7,446 shares during the quarter. AbbVie makes up about 3.5% of Welch Group LLC's portfolio, making the stock its 3rd biggest position. Welch Group LLC's holdings in AbbVie were worth $56,801,000 as of its most recent filing with the Securities and Exchange Commission.
據韋爾奇集團最近提交給美國證券交易委員會的文件顯示，該公司在第二季度減持了艾伯維公司股份2.0%。該機構投資者在本季度出售了7,446股後，持有該公司370,861股股票。AbbVie約佔Welch Group LLC投資組合的3.5%，使該股成為其第三大頭寸。截至最近提交給美國證券交易委員會的文件，韋爾奇集團持有的艾伯維股份價值56,801,000美元。
Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. Coastal Bridge Advisors LLC bought a new stake in AbbVie during the 4th quarter valued at $215,000. CastleKnight Management LP acquired a new stake in shares of AbbVie in the 4th quarter worth $325,000. Capital Planning Advisors LLC acquired a new stake in shares of AbbVie in the 4th quarter worth $207,000. Capital International Investors boosted its position in shares of AbbVie by 19.7% in the 4th quarter. Capital International Investors now owns 11,615,068 shares of the company's stock worth $1,572,680,000 after purchasing an additional 1,913,451 shares in the last quarter. Finally, CIBC World Markets Inc. boosted its position in shares of AbbVie by 8.5% in the 4th quarter. CIBC World Markets Inc. now owns 914,271 shares of the company's stock worth $123,792,000 after purchasing an additional 71,938 shares in the last quarter. Institutional investors own 68.25% of the company's stock.
其他幾家對衝基金和其他機構投資者也買賣了ABBV的股票。Coastal Bridge Advisors LLC在第四季度購買了AbbVie的新股份，價值21.5萬美元。CastleKnight Management LP在第四季度收購了AbbVie價值325,000美元的新股份。資本規劃顧問有限責任公司在第四季度收購了AbbVie價值20.7萬美元的新股份。Capital International Investors在第四季度將其在AbbVie股票的頭寸增加了19.7%。Capital International Investors現在擁有11,615,068股該公司股票，價值1,572,680,000美元，上個季度又購買了1,913,451股。最後，加拿大帝國商業銀行World Markets Inc.在第四季度將其在AbbVie股票的持倉增加了8.5%。加拿大帝國商業銀行World Markets Inc.目前持有914,271股該公司股票，價值123,792,000美元，上個季度又購買了71,938股。機構投資者持有該公司68.25%的股份。
AbbVie Stock Performance
艾伯維股票表現
NYSE ABBV opened at $134.21 on Friday. The stock has a 50-day simple moving average of $141.00 and a two-hundred day simple moving average of $149.13. The firm has a market capitalization of $237.30 billion, a P/E ratio of 19.01, a PEG ratio of 4.01 and a beta of 0.72. AbbVie Inc. has a fifty-two week low of $106.86 and a fifty-two week high of $175.91. The company has a debt-to-equity ratio of 4.15, a quick ratio of 0.75 and a current ratio of 0.84.
紐約證券交易所ABBV上週五開盤報134.21美元。該股的50日簡單移動均線切入位為141.00美元，200日簡單移動均線切入位為149.13美元。該公司市值為2373億美元，市盈率為19.01倍，聚乙二醇率為4.01倍，貝塔係數為0.72倍。艾伯維公司股價跌至52周低點106.86美元，52周高點175.91美元。該公司的負債權益比率為4.15，速動比率為0.75，流動比率為0.84。
AbbVie Dividend Announcement
AbbVie股息公告
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 15th. Stockholders of record on Friday, October 14th will be given a dividend of $1.41 per share. This represents a $5.64 dividend on an annualized basis and a dividend yield of 4.20%. The ex-dividend date is Thursday, October 13th. AbbVie's dividend payout ratio (DPR) is presently 79.89%.
該公司最近還宣佈了季度股息，將於11月15日(星期二)支付。10月14日(星期五)登記在冊的股東將獲得每股1.41美元的股息。這意味着年化股息為5.64美元，股息收益率為4.20%。除息日期為10月13日星期四。AbbVie的股息支付率(DPR)目前為79.89%。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of analysts have recently weighed in on ABBV shares. Morgan Stanley lowered their price objective on AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a research report on Monday, August 1st. Argus lowered their price objective on AbbVie from $165.00 to $155.00 and set a "buy" rating for the company in a research report on Wednesday, August 24th. Piper Sandler reduced their target price on AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Barclays reduced their target price on AbbVie to $160.00 in a research note on Tuesday, August 9th. Finally, Atlantic Securities reduced their target price on AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a research note on Monday, August 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $159.35.
一些分析師最近加入了ABBV股票的行列。8月1日，摩根士丹利在一份研究報告中將艾伯維的目標價從191.00美元下調至188.00美元，並對該公司設定了“增持”評級。8月24日，Argus在一份研究報告中將AbbVie的目標價從165.00美元下調至155.00美元，並對該公司設定了“買入”評級。派珀·桑德勒在7月29日星期五的一份研究報告中將他們對AbbVie的目標價從160.00美元下調至155.00美元。巴克萊在8月9日週二的一份研究報告中將AbbVie的目標價下調至160.00美元。最後，大西洋證券在8月1日週一的一份研究報告中將AbbVie的目標價從178.00美元下調至162.00美元，並將該公司的評級定為“中性”。一位研究分析師對該股的評級為賣出，6位分析師給出了持有評級，9位分析師給出了買入評級，一位分析師給出了強烈的買入評級。根據MarketBeat.com的數據，該公司的平均評級為“適度買入”，共識目標價為159.35美元。
AbbVie Profile
AbbVie個人資料
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA，用於注射治療自身免疫和腸道Behçet‘s疾病；SKYRIZI用於治療成人中到重度斑塊型牛皮癬；RINVOQ，用於治療成人患者的中到重度活動性類風濕性關節炎；IMBRUVICA，用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤；以及VENCLEXTA，用於治療成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何？
- 利潤下降對CarMax價值主張的挑戰
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Get Rating).
想看看其他對衝基金持有ABBV嗎？訪問HoldingsChannel.com獲取艾伯維公司的最新13F文件和內幕交易。
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。